Rakovina Therapeutics to Present at the Emerging Growth Conference on April 19, 2023 VANCOUVER, British Columbia, April 17, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”) is pleased to announce that it has been invited to present at...

Rakovina Therapeutics Inc. Announces Enhanced Liquidity and Investor Awareness Programs VANCOUVER, British Columbia, March 30, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (the “Company”) (TSXV:RKV) today announced the engagement of Red Cloud Securities (“Red Cloud”) and...

Rakovina Therapeutics Inc. Announces Plan to Apply to Extend Warrant Expiry Dates VANCOUVER, British Columbia, March 10, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (the “Company”) (TSXV:RKV) announces that it may apply to the TSX Venture Exchange (the “TSXV”) to extend...

Rakovina Therapeutics to Present at the Emerging Growth Conference on November 30, 2022 VANCOUVER, British Columbia, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new cancer...

Rakovina Therapeutics Inc. Announces Q3 2022 Financial Results and Provides Corporate Update VANCOUVER, British Columbia, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on...